<DOC>
	<DOCNO>NCT01682603</DOCNO>
	<brief_summary>To investigate clinical effect detrusor botulinum toxin A ( BoNT-A ) injection neurogenic detrusor overactivity ( NDO ) renal function compare difference expression sensory receptor nerve growth factor ( NGF ) bladder wall patient respond respond BoNT-A injection chronic spinal cord injure ( SCI ) patient .</brief_summary>
	<brief_title>Effect Botulinum Toxin A Detrusor Overactivity Renal Function Chronic Spinal Cord Injured Patients</brief_title>
	<detailed_description>Study Procedure A total 30 patient chronic suprasacral cord SCI enrol study . All patient 18 year old chronic suprasacral cord injury 1 year . They previously undergo urodynamic study proven detrusor sphincter dyssynergia ( DSD ) . The patient currently void reflex , abdominal stimulation clean intermittent catheterization ( CIC ) , free indwell catheter cystostomy , free urinary tract infection ( UTI ) enrollment . During screen period , total glomerular filtration rate ( GFR ) less 80 mL/min measure 99mTc-labelled diethylenetriamine pentaacetic acid ( 99mTc-DTPA ) clearance renal scanning . Patients also adequate hand function care-giver available CIC . Other exclusion criterion include patient detrusor underactivity large bladder compliance , patient prove intrinsic sphincteric deficiency patient hypersensitivity botulinum toxin A ( BTX-A ) constituent ingredient BTX-A . BTX-A injection perform operation room light intravenous general anesthesia prevent autonomic dysreflexia hyperreflexia cystoscopy . A total 300U BTX-A ( BOTOX , 100 U/vial , Allergan Co. , Irvine , USA ) dissolve 30 mL normal saline inject 30 site bladder include lateral , posterior wall dome . The injection sit widely distribute cover whole bladder wall . A 14 Fr Foley catheter routinely insert BTX-A injection patient discharge next morning follow out-patient clinic . All patient instruct keep CIC abdominal stimulation previously perform . BTX-A injection repeat 6 month first treatment , follow 24 month . Before BTX-A injection videourodynamic study GFR test perform . Patients also request report severity urinary incontinence mean daily incontinence episode within three day , Urogenital Distress Inventory ( UDI-6 Short Form ) , Incontinence Impact Questionnaire ( IIQ-7 ) , self assess QoL index global satisfaction rate ( grade 0 3 , indicate none , mild , moderate satisfy ) treatment . The adverse event urinary tract infection , hematuria , difficult urination also record . This study approve Institutional Review Board Ethics Committee hospital . Informed consent obtain screen patient instruct possible complication relate BTX-A injection urinary retention , transient hematuria subsequent urinary tract infection . Patients classified responder non-responders accord clinical presentation urodynamic study result . Responders consider become dry reduction incontinence episodes 50 % decrease detrusor pressure reduction 50 % baseline value , otherwise , consider non-responders . The end-point set 6 month BTX-A injection . There two primary end-points : ( 1 ) net change IIQ-7 UDI-6 baseline 24 month , ( 2 ) net change GFR baseline 24 month . Secondary end-point efficacy measure net change cystometric bladder capacity , bladder compliance , detrusor pressure reflex voiding , end-filling pressure detrusor leak-point pressure postvoid residual volume baseline 24 month . Three bladder biopsy use small cystoscopic biopsy forceps perform patient . The biopsy perform baseline time-point prior intravesical BTX-A injection . The bladder biopsy specimens sent pathological department H-E stain exclude possibility carcinoma situ , also embed O.C.T . medium store -80â„ƒ refrigerator liquid nitrogen tank investigation . The bladder biopsy prepare measurement NGF messenger RNA ( mRNA ) immunohistochemistry investigation expression Transient Receptor Potential Vanilloid 1 ( TRPV-1 ) , purinergic receptor P2X , ligand-gated ion channel , 3 ( P2X3 ) receptor baseline 6 month BTX-A injection , difference sensory protein expression responder .non-responders BTX-A injection .</detailed_description>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Adults age 19 year old Patients chronic suprasacral cord SCI enrol . Patients proven NDO videourodynamic study screen period . They also receive 99mTcDTPA renal scan GFR baseline . Patients NDO induce urinary incontinence adequate hand function caregiver available CIC , baseline total GFR le 80 mL/min main inclusion criterion Patients detrusor underactivity large bladder compliance , patient prove intrinsic sphincteric deficiency Patients hypersensitivity BTXA constituent ingredient BTXA .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Nerve growth factor</keyword>
	<keyword>P2X3 receptor</keyword>
	<keyword>Transient Receptor Potential Vanilloid 1 ( TRPV-1 ) receptor</keyword>
	<keyword>Bladder function</keyword>
	<keyword>Glomerular filtration rate</keyword>
	<keyword>Detrusor overactivity</keyword>
	<keyword>Spinal cord injury</keyword>
</DOC>